Please login to the form below
neurology
This page shows the latest neurology news and features for those working in and with pharma, biotech and healthcare.
Sage’s postpartum depression treatment Zulresso gains US approval
The company recently raised $575m to fund its pipeline, including other assets such as lead neurology candidate SAG-324 for essential tremor and epileptiform disorders, and neuropsychiatry candidate SAGE-718 for
Latest news
-
Urovant slips on phase 3 incontinence drug data
That strategy notably came unstuck at its Axovant unit, which posted a series of failed dementia studies with two licensed candidates before abandoning its neurology focus and re-inventing itself as
-
Sage raises $575m ahead of FDA review date for Zulresso
The cash injection will also help Sage bring forward its lead neurology candidate SAG-324 for essential tremor and epileptiform disorders, and neuropsychiatry candidate SAGE-718 for cognition-related disorders such
-
Medicinal cannabis firm Althea enters UK market
the advice of the British Paediatric Neurology Association (BPNA), which says it cannot recommend drugs that haven’t undergone testing.
-
Alector kicks off next wave of biotech IPOs
US biotech raising money again. The US government shutdown of 35 days had deterred new IPOs in biotech, but market launches have now resumed with immune-neurology specialists Alector. ... Alector is pioneering immuno-neurology, a novel therapeutic that
-
Novartis files for approval of MS drug in EU, US
In the EXPAND study presented at this year’s American Academy of Neurology (AAN) conference, siponimod showed a 14-20% reduced risk of disability progression in SPMS compared to placebo at
More from news
Approximately 5 fully matching, plus 130 partially matching documents found.
Latest Intelligence
-
Brain power: fresh approaches to Alzheimer’s drug discovery
US biotech company Alector, which is pioneering work in immuno-neurology and novel therapeutic approaches to treating neurodegeneration, raised $176m in an initial public offering in early February.
-
Tackling a formidable foe
Ali-Frederic Ben-Amor, Vice President, Global Medical Affairs for Neurology &Immunology, Merck. ... Ali-Frederic Ben-Amor, Vice President, Global Medical Affairs for Neurology &Immunology, Merck, epitomises the field’s passion and refusal to take a
-
A quest for innovative solutions
Ecosystem. “I have the most beautiful job in the company because my team and I are exposed to the change externally,” says Erik Janssen, UCB’s head of innovative solutions, Neurology
-
The good, the bad and the ugly
Biogen was the largest seller in the CNS market in 2017 and this is forecast to continue,” says Rahael Maladwala, analyst, neurology and ophthalmology, GlobalData. ... Neurology experienced slow growth, largely because few diseases are very well
-
Deal Watch October 2016
$330m. Neurology 2016. Aspen. 5 anesthetics. $770m royalties. $592m. 1.3. Neurology 2014. ... Lilly. AZD3293. $500 profit share. Neurology 2012. Impax US. Zomig US.
More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.
Latest appointments
-
Axovant poaches Allergan’s and Teva’s chief medical and science officers
Corcoran’s career history has seen him supervise drug development across multiple therapeutic areas including neurology and psychiatry.
-
Topas Therapeutics appoints chief development officer and chief medical officer
vice president, multiple sclerosis/neurology and immunology.
-
GW Pharmaceuticals strengthens research and development team
Volker has an impressive record of successful new drug development and obtaining regulatory approvals which together with his deep experience in neurology, makes him ideally suited to lead GW’s clinical
-
Sam Agus takes up new role at Hansa Medical
Agus has previously held various leading positions at several pharmaceutical companies includingAbbott Laboratories and most recently at H.Lundbeck A/S as it’s chief specialist, medical affairs neurology. ... With experience in medical strategy,
-
J&J’s clinical research neuroscience director joins MedAvante
He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition to MedAvante's scientific leadership team.”.
More from appointments
Approximately 0 fully matching, plus 30 partially matching documents found.
Latest from PMHub
-
Innovative approaches in the treatment of multiple sclerosis
Blue Latitude Health Senior Associate Consultant Will Frostick delves into the MS treatment landscape and explores some of the cutting-edge treatments on the horizon. Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central
-
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry. Inside this downloadable pack, you’ll find a
-
Six factors that drive a multiple sclerosis patient's choice of disease-modifying therapy
MS advocate Trishna Bharadia explains the numerous factors that lead patients to choose a disease-modifying therapy, including the important considerations healthcare professionals and pharma often forget. MS advocate Trishna Bharadia explains the
-
Innovative approaches in the treatment of multiple sclerosis
Senior Associate Consultant Will Frostick delves into the MS treatment landscape and explores some of the cutting-edge treatments on the horizon. Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS),
-
Q&A with Dr Timothy Vollmer, leading MS Neurologist
TV:My aunt died of MS when I was a child. Then, when I went to medical school, I was interested in neurology but I found I was best at immunology.
More from PMHub
Approximately 7 fully matching, plus 11 partially matching documents found.
Featured jobs
-
Health Consultant - Brand Comms
-
Competitive Salary
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
-
Digital Account Director
-
Salary TBC
- Home-based Senior Medical Writer – Med Ed
-
Salary TBC
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Associate Director – Social Healthcare – London
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
-
Account Director, Medical Education
-
Salary TBC
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Scientific Director – Medical Communications
-
Salary TBC
- Senior Account Manager, Medical Communications, London
-
Excellent package
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Senior Medical Writer
-
Salary TBC
Subscribe to our email news alerts
- Fishawack acquires Dudnyk
- GSK’s myeloma drug hits target, prompting rapid filing pledge
- Winners of the HSJ Partnership Awards 2019 unveiled
- 50 questions for delivering an exceptional healthcare brand experience
- Celgene and Exscientia sign AI drug discovery deal in oncology and autoimmunity
- The brand strategy revolution
PMHub
Nobull Communications
Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...
Latest intelligence
- 50 questions for delivering an exceptional healthcare brand experience
- Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
- The brand strategy revolution
- Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
- How Medisafe is using AI to improve patient adherence
- Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Quick links
Infographics
